ESMO 2022 | Unanswered questions regarding the use of first-line therapy in mCRC

Armando Orlandi, MD, PhD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, discusses the possible benefits of using a de-escalation strategy in the first-line for patients with metastatic colorectal cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.